New Data Show Roche's Self-Administered Blood Disorder Candidate Achieves Disease Control
Portfolio Pulse from Vandana Singh
Roche's phase 3 COMMODORE 1 and 2 studies show that crovalimab is non-inferior to AstraZeneca's eculizumab in treating paroxysmal nocturnal hemoglobinuria (PNH). The self-administered crovalimab has the potential to address the high burden of lifelong treatment and improve access to C5 inhibitors.
June 09, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Roche's crovalimab shows non-inferiority to AstraZeneca's eculizumab in treating PNH, potentially increasing competition in the C5 inhibitor market.
Roche's crovalimab demonstrated non-inferiority to AstraZeneca's eculizumab in treating PNH. This could potentially increase competition in the C5 inhibitor market, which may negatively impact AstraZeneca's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 100
POSITIVE IMPACT
Roche's crovalimab shows promising results in phase 3 studies, potentially improving access to C5 inhibitors for PNH patients.
Roche's crovalimab demonstrated non-inferiority to AstraZeneca's eculizumab in treating PNH. The self-administered crovalimab has the potential to address the high burden of lifelong treatment and improve access to C5 inhibitors, which could positively impact Roche's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100